BRPI0607475B8 - promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática - Google Patents

promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática

Info

Publication number
BRPI0607475B8
BRPI0607475B8 BRPI0607475A BRPI0607475A BRPI0607475B8 BR PI0607475 B8 BRPI0607475 B8 BR PI0607475B8 BR PI0607475 A BRPI0607475 A BR PI0607475A BR PI0607475 A BRPI0607475 A BR PI0607475A BR PI0607475 B8 BRPI0607475 B8 BR PI0607475B8
Authority
BR
Brazil
Prior art keywords
pancreatic
promoter
cell
insulin production
beta
Prior art date
Application number
BRPI0607475A
Other languages
English (en)
Inventor
Takashi Akamizu
Taiga Irako
Kenji Kangawa
Shuichi Koda
Naomi Wakabayashi
Original Assignee
Asubio Pharma Co Ltd
Daiichi Sankyo Co Ltd
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36927405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607475(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asubio Pharma Co Ltd, Daiichi Sankyo Co Ltd, Univ Kyoto filed Critical Asubio Pharma Co Ltd
Publication of BRPI0607475A2 publication Critical patent/BRPI0607475A2/pt
Publication of BRPI0607475B1 publication Critical patent/BRPI0607475B1/pt
Publication of BRPI0607475B8 publication Critical patent/BRPI0607475B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

promotor de regeneração de célula (beta) pancreática, e promotor de produção de insulina em célula (beta) pancreática. a presente invenção refere-se a um fármaco para promover neogênese ou regeneração de células (beta) pancreáticas que produzem e secretam insulina e para promover a produção de insulina em células (beta), compreendendo grelina ou um derivado desta como um componente efetivo.
BRPI0607475A 2005-02-23 2006-02-23 promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática BRPI0607475B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005046562 2005-02-23
JP2005-046562 2005-02-23
JP2006-003219 2006-01-11
JP2006003219 2006-01-11
PCT/JP2006/303243 WO2006090767A1 (ja) 2005-02-23 2006-02-23 膵臓β細胞の再生促進剤及び膵臓β細胞におけるインスリン産生促進剤

Publications (3)

Publication Number Publication Date
BRPI0607475A2 BRPI0607475A2 (pt) 2009-09-08
BRPI0607475B1 BRPI0607475B1 (pt) 2020-02-11
BRPI0607475B8 true BRPI0607475B8 (pt) 2021-05-25

Family

ID=36927405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607475A BRPI0607475B8 (pt) 2005-02-23 2006-02-23 promotor de regeneração de célula ß pancreática, e promotor de produção de insulina em célula ß pancreática

Country Status (11)

Country Link
US (1) US7803768B2 (pt)
EP (1) EP1862173B1 (pt)
JP (1) JP4843827B2 (pt)
KR (1) KR101295104B1 (pt)
CN (1) CN101128213B (pt)
AU (1) AU2006216218B2 (pt)
BR (1) BRPI0607475B8 (pt)
CA (1) CA2598864C (pt)
IL (1) IL184931A (pt)
RU (1) RU2403058C2 (pt)
WO (1) WO2006090767A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100056507A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ｐｒｏ－ｇｌｙ－ｔｈｒ－ｃｙｓ－ｇｌｕ－ｉｌｅ－ｃｙｓ－ａｌａ－ｔｙｒ－ａｌａ－ａｌａ－ｃｙｓ－ｔｈｒ－ｇｌｙ－ｃｙｓ의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401939T3 (es) 1999-07-23 2013-04-25 Kenji Kangawa Nuevos péptidos
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
JP4493913B2 (ja) 2001-01-31 2010-06-30 中外製薬株式会社 低栄養症状疾患治療剤
AU2002351593A1 (en) * 2001-12-18 2003-06-30 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2004004772A1 (ja) * 2002-07-05 2004-01-15 Chugai Seiyaku Kabushiki Kaisha 糖尿病治療剤
US7825090B2 (en) * 2003-10-24 2010-11-02 Alizé Pharma SAS Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance
US20090149512A1 (en) * 2004-05-14 2009-06-11 Novo Nordisk A/S Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases

Also Published As

Publication number Publication date
EP1862173B1 (en) 2014-12-17
CA2598864A1 (en) 2006-08-31
CN101128213B (zh) 2013-05-08
RU2403058C2 (ru) 2010-11-10
JP4843827B2 (ja) 2011-12-21
EP1862173A4 (en) 2012-03-28
KR20070110856A (ko) 2007-11-20
US7803768B2 (en) 2010-09-28
JPWO2006090767A1 (ja) 2008-07-24
CA2598864C (en) 2016-02-16
US20090143284A1 (en) 2009-06-04
AU2006216218A1 (en) 2006-08-31
EP1862173A1 (en) 2007-12-05
WO2006090767A1 (ja) 2006-08-31
IL184931A0 (en) 2007-12-03
CN101128213A (zh) 2008-02-20
BRPI0607475B1 (pt) 2020-02-11
IL184931A (en) 2011-08-31
RU2007135225A (ru) 2009-03-27
KR101295104B1 (ko) 2013-08-09
BRPI0607475A2 (pt) 2009-09-08
AU2006216218B2 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
UA107812C2 (xx) ДВОЗАМІЩЕНІ ОКТАГІДРОПІРОЛО$3,4-с]ПІРОЛИ ЯК МОДУЛЯТОРИ ОРЕКСИНОВИХ РЕЦЕПТОРІВ
BRPI0815308A2 (pt) peptídeo das pró-ilhotas de lagerhans, composição farmacûtica, método para estimular na neogêneses das ilhotas ou estimular a regeneração das ilhotas de langerhans e método para tratar uma patologia associada com a função pancreática defeituosa em um indivíduo
MX346428B (es) Metodo para tratar eccema.
CL2009000782A1 (es) Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades.
BRPI0920914A8 (pt) Perácidos alfa-ceto e métodos para produzir e usar os mesmos.
BR112012011403A2 (pt) composição farmacêutica compreendendo um agonista glp-1 e metionina
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112013010551A2 (pt) variantes de isopreno sintase para a produção aprimorada de isopreno
CL2007002682A1 (es) Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
BRPI0715176A8 (pt) compostos de heteroarila utéis como inibidores de enzimas de ativação e1
GT201200153A (es) Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
NI200900190A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. pc33495a
BR112012011128A2 (pt) composição farmacêutica compreendendo um agonista de glp-1, uma insulina e uma metionina
BRPI0914684C1 (pt) uso de hsp70 ou um fragmento funcional ou variante do mesmo, e, hsp70 ou um fragmento funcional ou variante do mesmo
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
MX368000B (es) Composición de colágeno y ácido hialurónico para la reparación de ligamento o tendón.
BRPI0720099A2 (pt) Pilha de células de combustível e vedação para uma pilha de células de combustível, bem como processo de produção para a mesma
CL2011003079A1 (es) Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes.
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
BR112012008004A2 (pt) compostos e composições como moduladores da atividade de gpr119
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: KYOTO UNIVERSITY (JP) , DAIICHI SANKYO COMPANY, LI

Free format text: TRANSFERIDO POR INCORPORACAO DE: ASUBIO PHAMA CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP)